NCT03768037 is a Phase 4 clinical trial of Anlotinib plus Pemetrexed in Advanced Non-squamous NSCLC, sponsored by Guangdong Association of Clinical Trials.

Who is sponsoring NCT03768037?

NCT03768037 is sponsored by Guangdong Association of Clinical Trials.

What drugs are being tested in NCT03768037?

Interventions in NCT03768037: Anlotinib plus Pemetrexed, Pemetrexed.

What condition does NCT03768037 study?

NCT03768037 studies Advanced Non-squamous NSCLC.

Is NCT03768037 still recruiting?

NCT03768037 is currently status unknown. Last updated 7 December 2018.

Last reviewed 2018-12-07 · How we verify

NCT03768037

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Status unknown Phase 4 Last updated 7 December 2018

What this trial tests

Phase 4 trial testing Anlotinib plus Pemetrexed in Advanced Non-squamous NSCLC in 106 participants. Status unknown.

Timeline

26 November 2018

Primary endpoint
26 November 2019

26 November 2020

Quick facts

Lead sponsor	Guangdong Association of Clinical Trials
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	106
Start date	26 November 2018
Primary completion	26 November 2019
Estimated completion	26 November 2020
Sites	1 location across China

Drugs / interventions tested

Anlotinib plus Pemetrexed — full drug profile →
Pemetrexed — full drug profile →

Conditions studied

Advanced Non-squamous NSCLC — all drugs for Advanced Non-squamous NSCLC →

Sponsor

Guangdong Association of Clinical Trials

Who can join

Adults 18 to 120, any sex, with Advanced Non-squamous NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Anlotinib plus Pemetrexed

Trials testing the same drug.

NCT03778138 — Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC · Phase 2 · unknown

Other Guangdong Association of Clinical Trials trials

Trials by the same sponsor.

NCT07412262 — A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment · Phase 2 · not yet recruiting
NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting
NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
NCT07198620 — A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03768037 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Association of Clinical Trials
Last refreshed: 7 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03768037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing